Holen Sie sich die Stockscreener-App
0.9111
4.60%
-0.0439
Schlusskurs vom Vortag:
$0.955
Offen:
$0.95
24-Stunden-Volumen:
140.75K
Relative Volume:
0.91
Marktkapitalisierung:
$10.36M
Einnahmen:
$3,000
Nettoeinkommen (Verlust:
$-8.23M
KGV:
-0.6458
EPS:
-1.4107
Netto-Cashflow:
$-7.44M
1W Leistung:
-4.19%
1M Leistung:
-21.46%
6M Leistung:
-36.29%
1J Leistung:
-53.75%
1-Tages-Spanne:
$0.9102
$0.97
1-Wochen-Bereich:
$0.8807
$0.97
52-Wochen-Spanne:
$0.8404
$2.45
Biocardia Inc Stock (BCDA) Company Profile
Firmenname
Biocardia Inc
Sektor
Branche
Telefon
650-226-0123
Adresse
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.40 | 2.93B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
7.50 | 432.93M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.13 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.29 | 288.61M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.54 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-16 | Herabstufung | Dawson James | Buy → Neutral |
Biocardia Inc Aktie (BCDA) Neueste Nachrichten
BioCardia outlines Japan Shonin filing in ~7 months and targets ~19-month path to approval for CardiAMP - MSN
BioCardia CEO Peter Altman buys $1,570 in company stock - Investing.com
BioCardia (NASDAQ: BCDA) CEO adds 1,700 shares in May open‑market buys - Stock Titan
BioCardia reports positive results from CardiAMP CMI trial By Investing.com - Investing.com Nigeria
BioCardia Announces Positive CardiAMP Chronic Myocardial Ischemia Trial Results with Reduced Angina at EuroPCR 2026 - Minichart
BioCardia reports positive results from CardiAMP CMI trial - Investing.com UK
BioCardia Announces Encouraging CardiAMP Chronic Ischemia Data - TipRanks
BioCardia reports durable exercise gains, 82% angina reduction in CardiAMP CMI open-label cohort - TradingView
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency - The Manila Times
BioCardia (NASDAQ: BCDA) posts CardiAMP CMI data with durable angina and exercise gains - Stock Titan
Heart cell therapy linked to longer walks, 82% fewer angina attacks - Stock Titan
BioCardia president and CEO Peter Altman buys $5,244 in stock By Investing.com - Investing.com Nigeria
BioCardia, Inc. (NASDAQ:BCDA) Q1 2026 Earnings Call Transcript - Insider Monkey
BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase - The Manila Times
Watch BioCardia’s virtual fireside chat at A.G.P. healthcare showcase - Stock Titan
BioCardia Reports Promising CardiAMP Cell Therapy Data in Q1 2026 Conference Call - IndexBox
BioCardia president and CEO Peter Altman buys $5,244 in stock - Investing.com UK
BioCardia (BCDA) CEO buys 5,700 shares in open-market purchase - Stock Titan
BioCardia (BCDA) Q1 2026 Earnings Transcript - AOL.com
BioCardia Q1 2026: -$0.21 EPS Falls Short — Deep Dive - AlphaStreet
BCDA Stock Price, Quote & Chart | BIOCARDIA INC (NASDAQ:BCDA) - ChartMill
Q1 2026 BioCardia Inc Earnings Call Transcript - GuruFocus
BioCardia, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
BioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthroughs in Cardiac Therapy and ... By GuruFocus - Investing.com Canada
Key facts: CardiAMP advances in US, Japan; FDA flags two Helix paths - TradingView
BioCardia (BCDA) Q1 2026: EPS Not Disclosed, Revenue Not Disclos - GuruFocus
BioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthro - GuruFocus
Insider Buying: Peter Altman Acquires Additional Shares of BioCa - GuruFocus
Earnings call transcript: Biocardia Q1 2026 highlights clinical progress By Investing.com - Investing.com Nigeria
BioCardia CEO Peter Altman buys $5,202 in company stock - Investing.com
BioCardia CEO Peter Altman buys $5,202 in company stock By Investing.com - Investing.com South Africa
BCDA: CardiAMP therapy advances toward Japanese approval, targeting a $400M market with strong clinical data - TradingView
Earnings call transcript: Biocardia Q1 2026 highlights clinical progress - Investing.com UK
BioCardia (BCDA) CEO Peter Altman makes open-market stock purchase - Stock Titan
BioCardia Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BioCardia Q1 2026 Earnings Call: Complete Transcript - Benzinga
BCDA - Finviz
MSN Money - MSN
BioCardia Releases Q1 2026 Financial Results - AlphaStreet
BioCardia, Inc. (BCDA) Files Form 8-K: Financial Results, SEC Disclosures, and NASDAQ Listing for May 2026 - Minichart
BioCardia Inc (NASDAQ:BCDA) Q1 Earnings Miss Overshadows Clinical Progress - ChartMill
BIOCARDIA ($BCDA) Releases Q1 2026 Earnings - Quiver Quantitative
BioCardia reports Q1 2026 net loss of $2.3M, cash $951K and ongoing regulatory progress - TradingView
BCDA: Advanced regulatory milestones and improved financials, but cash reserves declined - TradingView
BioCardia, Inc. 1Q 2026: Net loss $(2.26)M, EPS $(0.21) — 10-Q Summary - TradingView
BioCardia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Finanzdaten der Biocardia Inc-Aktie (BCDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biocardia Inc-Aktie (BCDA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
May 19 '26 |
Buy |
0.95 |
200 |
190 |
291,766 |
| Altman Peter | President and CEO |
May 18 '26 |
Buy |
0.92 |
5,700 |
5,244 |
291,566 |
| Altman Peter | President and CEO |
May 15 '26 |
Buy |
1.02 |
5,100 |
5,202 |
285,866 |
| Altman Peter | President and CEO |
Apr 29 '26 |
Buy |
1.11 |
5,000 |
5,550 |
280,766 |
| Altman Peter | President and CEO |
Apr 20 '26 |
Buy |
1.23 |
600 |
738 |
275,366 |
| Altman Peter | President and CEO |
Apr 21 '26 |
Buy |
1.23 |
400 |
492 |
275,766 |
| Altman Peter | President and CEO |
Mar 24 '26 |
Buy |
1.24 |
600 |
744 |
274,466 |
| Altman Peter | President and CEO |
Mar 25 '26 |
Buy |
1.22 |
300 |
366 |
274,766 |
| Altman Peter | President and CEO |
Feb 04 '26 |
Buy |
1.13 |
5,000 |
5,650 |
273,866 |
| Altman Peter | President and CEO |
Jan 20 '26 |
Buy |
1.32 |
600 |
792 |
268,566 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):